- Stocks
- Pharma & Healthcare
- Eris Lifesciences
Eris Lifesciences share price
NSE: ERISPharma & HealthcareDrug Manufacturers - Specialty & Generic
Eris Lifesciences at a glance
Eris Lifesciences (NSE: ERIS) closed at ₹1,114.90 on 19 Oct 2026, down 2.36% on the day. With a market capitalisation of ₹15,450 Cr, it ranks 422nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 24.6× trailing earnings, against a return on equity of 15.9% in FY26. Over the past year the share price has fallen 30.0%. Its 52-week range is ₹1,111.10 (19 Oct 2026) to ₹1,740.00 (9 Dec 2025); the last close is 35.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹869 Cr (+12.6% year on year) and net profit ₹144 Cr (+15.7%), on a consolidated basis. Promoters held 54.14% of the company as of 30 Jun 2026; 16.85% of promoter shares were pledged.
Key numbers
- Market cap
- ₹15,450 CrRank 422 on NSE
- P/E (trailing)
- 24.6×
- Price to book
- 4.61×FY26
- EPS (TTM)
- ₹47.02to Q1 FY27
- ROE
- 15.9%FY26
- ROCE
- 16.0%FY26
- Debt to equity
- 0.59FY26
- Net profit margin
- 20.7%FY26
- Book value / share
- ₹281.78FY26
- 52-week high
- ₹1,740.009 Dec 2025
- 52-week low
- ₹1,111.1019 Oct 2026
- 1-year return
- −30.0%
- RSI (14-day)
- 26.2
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.36% | −3.3% | −16.7% | −23.9% | −30.0% |
Eris Lifesciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹739 Cr | ₹722 Cr | ₹703 Cr | ₹772 Cr | ₹790 Cr | ₹801 Cr | ₹752 Cr | ₹869 Cr |
| Revenue YoY | +46.2% | +49.4% | +28.4% | +7.8% | +6.9% | +10.9% | +7.1% | +12.6% |
| Net profit | ₹96 Cr | ₹87 Cr | ₹102 Cr | ₹124 Cr | ₹134 Cr | ₹109 Cr | ₹280 Cr | ₹144 Cr |
| Net profit YoY | −21.2% | −14.3% | +28.5% | +38.9% | +39.3% | +25.1% | +174.0% | +15.7% |
| Net margin | 13.0% | 12.0% | 14.6% | 16.1% | 17.0% | 13.6% | 37.3% | 16.5% |
| EPS | ₹6.73 | ₹6.15 | ₹6.90 | ₹8.66 | ₹8.82 | ₹7.32 | ₹20.60 | ₹10.28 |
Eris Lifesciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,212 Cr | ₹1,347 Cr | ₹1,685 Cr | ₹2,009 Cr | ₹2,894 Cr | — |
| Operating profit | ₹395 Cr | ₹442 Cr | ₹405 Cr | ₹431 Cr | ₹489 Cr | — |
| Net profit | ₹355 Cr | ₹406 Cr | ₹374 Cr | ₹397 Cr | ₹375 Cr | — |
| EPS (₹) | ₹26.00 | ₹30.00 | ₹28.00 | ₹29.00 | ₹26.00 | — |
| Cash from operations | ₹375 Cr | ₹378 Cr | ₹292 Cr | ₹486 Cr | ₹1,065 Cr | — |
| Total debt | ₹0 Cr | ₹45 Cr | ₹644 Cr | ₹655 Cr | ₹1,738 Cr | ₹956 Cr |
| Shareholders' equity | ₹1,576 Cr | ₹1,908 Cr | ₹2,196 Cr | ₹2,586 Cr | ₹2,854 Cr | ₹3,903 Cr |
Eris Lifesciences shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% |
| Foreign institutions | 8.43% | 8.40% | 7.21% | 6.85% | 6.39% | 5.75% |
| Domestic institutions | 18.07% | 18.17% | 19.36% | 20.32% | 20.35% | 20.72% |
| Non-institutions | 18.66% | 18.59% | 18.57% | 17.99% | 19.33% | 19.40% |
| Promoter shares pledged | 18.51% | 16.93% | 16.92% | 16.92% | 16.92% | 16.85% |
Eris Lifesciences vs peers
The listed Pharma & Healthcare companies nearest to Eris Lifesciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SYNGENESyngene International | ₹399.00 | +3.91% | −38.7% | ₹16,106 Cr | 50.6 | — |
| POLYMEDPoly Medicure | ₹1,550.00 | −2.21% | −18.6% | ₹15,711 Cr | 48.9 | — |
| APLLTDAlembic Pharmaceuticals | ₹799.00 | +1.14% | −15.8% | ₹15,705 Cr | 23.3 | — |
| ONESOURCEOnesource Specialty Pharma | ₹1,364.00 | −2.99% | −26.9% | ₹15,638 Cr | — | — |
| ERISEris Lifesciences | ₹1,114.90 | −2.36% | −30.0% | ₹15,450 Cr | 24.6 | — |
| ALIVUSAlivus Life Sciences | ₹1,257.80 | −3.91% | +35.0% | ₹15,438 Cr | 27.4 | — |
| ASTRAZENAstraZeneca Pharma India | ₹6,074.00 | +2.39% | −34.7% | ₹15,185 Cr | 81.2 | — |
Ask anything about Eris Lifesciences
Pivot answers on the live chart with evidence you can check, and tests strategies against ERIS's own history. Try: “Why has ERIS moved over the last three months?” · “Backtest a 50-day moving-average crossover on ERIS over five years” · “Compare ERIS with SYNGENE on margins and valuation”
Frequently asked questions about Eris Lifesciences
What is the share price of Eris Lifesciences today?
Eris Lifesciences (NSE: ERIS) last closed at ₹1,114.90 on 19 Oct 2026. Its 52-week high is ₹1,740.00 and its 52-week low is ₹1,111.10.
What is the market cap of Eris Lifesciences?
Eris Lifesciences' market capitalisation is ₹15,450 Cr (₹15,450 Cr) at the 19 Oct 2026 close, ranking 422nd among the NSE companies Pivot tracks.
What is the P/E ratio of Eris Lifesciences?
Eris Lifesciences trades at a trailing P/E of 24.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 48.9.
What is the ROE and ROCE of Eris Lifesciences?
Return on equity was 15.9% in FY26 and return on capital employed was 16.0% in FY26 (consolidated figures).
Is Eris Lifesciences a debt-free company?
No. Eris Lifesciences' debt-to-equity ratio was 0.59 in FY26, with total debt of ₹956 Cr.
What were Eris Lifesciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Eris Lifesciences reported revenue of ₹869 Cr, +12.6% year on year, and net profit of ₹144 Cr, +15.7% year on year.
How has Eris Lifesciences stock performed over the last year?
Eris Lifesciences' share price has fallen 30.0% over the past year, −23.9% over three months and −16.7% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Eris Lifesciences?
As of 30 Jun 2026: promoters 54.14%, foreign institutions 5.75%, domestic institutions 20.72%, non-institutions 19.40%. 16.85% of promoter shares were pledged.
Who are Eris Lifesciences' competitors?
The listed Pharma & Healthcare companies closest to Eris Lifesciences by market cap are Syngene International, Poly Medicure, Alembic Pharmaceuticals, Onesource Specialty Pharma, Alivus Life Sciences and AstraZeneca Pharma India.
Is Eris Lifesciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Eris Lifesciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ERIS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text